Insider Buy/Sell Details for the Biotechnology Industry — Last 3 Months
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (3461)
Krystal Biotech, Inc. (KRYS)
ROSSI DINO A — Director
Shares
3,095
Price
$331.43
Total Value
$1.03M
Shares Held After
50,040
% of Holdings
5.8%
Krystal Biotech, Inc. (KRYS)
ROSSI DINO A — Director
Shares
4,896
Price
$330.36
Total Value
$1.62M
Shares Held After
53,135
% of Holdings
8.4%
Krystal Biotech, Inc. (KRYS)
ROSSI DINO A — Director
Shares
7,428
Price
$329.60
Total Value
$2.45M
Shares Held After
58,031
% of Holdings
11.3%
Krystal Biotech, Inc. (KRYS)
ROSSI DINO A — Director
Shares
1,687
Price
$328.52
Total Value
$554.21K
Shares Held After
65,459
% of Holdings
2.5%
Krystal Biotech, Inc. (KRYS)
ROSSI DINO A — Director
Shares
5,226
Price
$327.39
Total Value
$1.71M
Shares Held After
67,146
% of Holdings
7.2%
Krystal Biotech, Inc. (KRYS)
ROSSI DINO A — Director
Shares
2,287
Price
$326.60
Total Value
$746.94K
Shares Held After
72,372
% of Holdings
3.1%
Krystal Biotech, Inc. (KRYS)
ROSSI DINO A — Director
Shares
341
Price
$325.60
Total Value
$111.03K
Shares Held After
74,659
% of Holdings
0.5%
Oruka Therapeutics, Inc. (ORKA)
Quinlan Paul T — General Counsel
Shares
3,847
Price
$111.14
Total Value
$427.55K
Shares Held After
31,034
% of Holdings
11.0%
Oruka Therapeutics, Inc. (ORKA)
Quinlan Paul T — General Counsel
Shares
9,193
Price
$110.00
Total Value
$1.01M
Shares Held After
34,881
% of Holdings
20.9%
Oruka Therapeutics, Inc. (ORKA)
Quinlan Paul T — General Counsel
Shares
10,200
Price
$109.11
Total Value
$1.11M
Shares Held After
44,074
% of Holdings
18.8%
Oruka Therapeutics, Inc. (ORKA)
Quinlan Paul T — General Counsel
Shares
14,696
Price
$107.97
Total Value
$1.59M
Shares Held After
54,274
% of Holdings
21.3%
Oruka Therapeutics, Inc. (ORKA)
Quinlan Paul T — General Counsel
Shares
10,434
Price
$107.14
Total Value
$1.12M
Shares Held After
68,970
% of Holdings
13.1%
Oruka Therapeutics, Inc. (ORKA)
Quinlan Paul T — General Counsel
Shares
3,630
Price
$106.05
Total Value
$384.96K
Shares Held After
79,404
% of Holdings
4.4%
AbCellera Biologics Inc. (ABCL)
Booth Andrew — Chief Financial Officer
Shares
37,200
Price
$10.32
Total Value
$383.90K
Shares Held After
482,800
% of Holdings
7.7%
Dyne Therapeutics, Inc. (DYN)
Friedl-Naderer Johanna — Chief Commercial Officer
Shares
226
Price
$26.28
Total Value
$5.94K
Shares Held After
153,982
% of Holdings
0.1%
Cue Biopharma, Inc. (CUE)
Meluzio Michael Vincent — VP, Prin. Accounting Officer
Shares
3
Price
$31.13
Total Value
$93.39
Shares Held After
48,961
% of Holdings
0.0%
Cue Biopharma, Inc. (CUE)
Meluzio Michael Vincent — VP, Prin. Accounting Officer
Shares
4,106
Price
$30.35
Total Value
$124.62K
Shares Held After
48,964
% of Holdings
7.7%
Cue Biopharma, Inc. (CUE)
Meluzio Michael Vincent — VP, Prin. Accounting Officer
Shares
1,519
Price
$29.37
Total Value
$44.61K
Shares Held After
53,070
% of Holdings
2.8%
OMEROS CORP (OMER)
Borges David J. — VP, Finance&CAO
Shares
5,000
Price
$16.95
Total Value
$84.75K
Shares Held After
0
% of Holdings
100.0%
Cue Biopharma, Inc. (CUE)
Ray Sumita — Chief Legal Compliance Officer
Shares
4
Price
$31.13
Total Value
$124.52
Shares Held After
118,545
% of Holdings
0.0%
Cue Biopharma, Inc. (CUE)
Ray Sumita — Chief Legal Compliance Officer
Shares
6,442
Price
$30.35
Total Value
$195.51K
Shares Held After
118,549
% of Holdings
5.2%
Cue Biopharma, Inc. (CUE)
Ray Sumita — Chief Legal Compliance Officer
Shares
2,383
Price
$29.37
Total Value
$69.99K
Shares Held After
124,991
% of Holdings
1.9%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
63,643
Price
$26.20
Total Value
$1.67M
Shares Held After
751,411
% of Holdings
7.8%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
94,415
Price
$26.20
Total Value
$2.47M
Shares Held After
1,045,735
% of Holdings
8.3%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
268,354
Price
$26.20
Total Value
$7.03M
Shares Held After
3,801,128
% of Holdings
6.6%
ROCKET PHARMACEUTICALS, INC. (RCKT)
Wilson Martin — General Counsel
Shares
3,493
Price
$3.38
Total Value
$11.81K
Shares Held After
674,484
% of Holdings
0.5%
ROCKET PHARMACEUTICALS, INC. (RCKT)
Shah Gaurav — CEO
Shares
2,837
Price
$3.38
Total Value
$9.59K
Shares Held After
1,058,887
% of Holdings
0.3%
4D Molecular Therapeutics, Inc. (FDMT)
Bizily Scott — Chief Legal Officer
Shares
1,635
Price
$12.00
Total Value
$19.62K
Shares Held After
8,617
% of Holdings
15.9%
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Shulman Joseph — Chief Technical Officer
Shares
5,079
Price
$119.75
Total Value
$608.21K
Shares Held After
15,915
% of Holdings
24.2%
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Garfield Alastair — Chief Scientific Officer
Shares
800
Price
$119.17
Total Value
$95.34K
Shares Held After
2,295
% of Holdings
25.8%
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Garfield Alastair — Chief Scientific Officer
Shares
3,400
Price
$118.28
Total Value
$402.17K
Shares Held After
3,095
% of Holdings
52.3%
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Garfield Alastair — Chief Scientific Officer
Shares
1,556
Price
$117.08
Total Value
$182.17K
Shares Held After
6,495
% of Holdings
19.3%
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Garfield Alastair — Chief Scientific Officer
Shares
2,007
Price
$116.11
Total Value
$233.03K
Shares Held After
8,051
% of Holdings
20.0%
Royalty Pharma plc (RPRX)
Coyne Terrance P. — EVP&CFO
Shares
1,772
Price
$59.14
Total Value
$104.80K
Shares Held After
0
% of Holdings
100.0%
Royalty Pharma plc (RPRX)
Coyne Terrance P. — EVP&CFO
Shares
9,230
Price
$58.59
Total Value
$540.75K
Shares Held After
1,772
% of Holdings
83.9%
Dyne Therapeutics, Inc. (DYN)
Lucera Erick — Chief Financial Officer
Shares
1,797
Price
$26.28
Total Value
$47.23K
Shares Held After
119,766
% of Holdings
1.5%
VERU INC. (VERU)
BARNETTE K GARY — Chief Scientific Officer
Shares
1,800
Price
$2.69
Total Value
$4.84K
Shares Held After
2,300
% of Holdings
78.3%
Dyne Therapeutics, Inc. (DYN)
Cox John — Director
Shares
4,986
Price
$26.28
Total Value
$131.03K
Shares Held After
363,165
% of Holdings
1.4%
Dyne Therapeutics, Inc. (DYN)
Kerr Douglas — Chief Medical Officer
Shares
1,556
Price
$26.28
Total Value
$40.89K
Shares Held After
167,599
% of Holdings
0.9%
Cue Biopharma, Inc. (CUE)
Lin Shao-Lee — Director
Shares
10,460
Price
$29.48
Total Value
$308.36K
Shares Held After
705,995
% of Holdings
1.5%
Cue Biopharma, Inc. (CUE)
Lin Shao-Lee — Director
Shares
2,375
Price
$28.11
Total Value
$66.76K
Shares Held After
716,455
% of Holdings
0.3%
Cue Biopharma, Inc. (CUE)
Lin Shao-Lee — Director
Shares
5,423
Price
$27.19
Total Value
$147.45K
Shares Held After
718,830
% of Holdings
0.7%
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Lee Jennifer Kayden — EVP, Head of North America
Shares
75,834
Price
$117.38
Total Value
$8.90M
Shares Held After
0
% of Holdings
100.0%
Oruka Therapeutics, Inc. (ORKA)
Agarwal Arjun — Senior Vice President, Finance
Shares
2,358
Price
$108.46
Total Value
$255.76K
Shares Held After
15,312
% of Holdings
13.3%
Oruka Therapeutics, Inc. (ORKA)
Agarwal Arjun — Senior Vice President, Finance
Shares
2,142
Price
$107.71
Total Value
$230.72K
Shares Held After
17,670
% of Holdings
10.8%
Oruka Therapeutics, Inc. (ORKA)
Agarwal Arjun — Senior Vice President, Finance
Shares
1,268
Price
$106.63
Total Value
$135.20K
Shares Held After
19,812
% of Holdings
6.0%
Oruka Therapeutics, Inc. (ORKA)
Agarwal Arjun — Senior Vice President, Finance
Shares
2,132
Price
$105.57
Total Value
$225.08K
Shares Held After
21,080
% of Holdings
9.2%
Oruka Therapeutics, Inc. (ORKA)
Agarwal Arjun — Senior Vice President, Finance
Shares
2,100
Price
$104.67
Total Value
$219.81K
Shares Held After
23,212
% of Holdings
8.3%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
240
Price
$512.36
Total Value
$122.97K
Shares Held After
324,443
% of Holdings
0.1%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
160
Price
$511.12
Total Value
$81.78K
Shares Held After
324,683
% of Holdings
0.0%
Showing 101–150 of 3461 transactions (page 3 of 70)